XASX
PER
Market cap70mUSD
Jan 29, Last price
0.06AUD
Name
Antisense Therapeutics Ltd
Chart & performance
P/E
—
P/S
64.60
EPS
—
Vol. 1Y
—
Shs. 5Y
26.65%
Rev. 5Y
-55.61%
Div Yld LY
—
Div Yld TTM
—
Revenues
2m
-11.14%
Net income
-11m
L+95.06%
CFO
-8m
L+4.44%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Key people
Chief Technology Officer · since 2025
James Garner
Chief Executive Officer, Managing Director, Executive Director · since 2023
Chief Commercial Officer · since 2022
Andrew Mckenzie
Clinical Development Director · since 2023
George Tachas
Director - Drug Discovery and Patents
Deborah Ambrosini
Chief Financial Officer, Company Secretary · since 2024
Non-Executive Independent Chairman of the Board · since 2023
Ben Price
Non-Executive Independent Director · since 2021
Legal address
35 COLLINS STREET
MELBOURNE, VIC 3000
AU
MELBOURNE, VIC 3000
AU
Headquarters
'THE EXECUTIVE CENTRE COLLINS PLACE', 35 COLLINS STREET
MELBOURNE, VIC 3000
AU
MELBOURNE, VIC 3000
AU
Previous name
ANTISENSE THERAPEUTICS LIMITED
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||